β.-L-阿洛吡喃糖,1,6-脱水-2,3-O-(苯基亚甲基)-,乙酸酯 | 71138-35-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: β.-L-阿洛吡喃糖,1,6-脱水-2,3-O-(苯基亚甲基)-,乙酸酯
• 英文名称: Desogestrel and ethinyl estradiol
• 英文别名: (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 71138-35-7
• 化学式: C42H54O3
• 分子量: 606.9
• InChiKey: MXBCYQUALCBQIJ-RYVPXURESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.48
• 重原子数：
  45
• 可旋转键数：
  3
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET
  申请人：FUJI CHEMICAL INDUSTRY CO., LTD.

  公开号：EP2465539A1

  公开（公告）日：2012-06-20

  There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.

  人们需要一种口服快速崩解片剂，这种片剂在口腔中具有良好的质地和口感，有足够的硬度，不会担心在生产或运输过程中碎裂或沾上灰尘，在口腔中具有良好的崩解性能，即使在开封后潮湿的条件下也能保持足够的硬度。本发明公开了一种崩解颗粒组合物，其制备方法是在有水存在的情况下，将甘露醇、木糖醇、无机赋形剂、崩解剂和卡麦芽糖分散并干燥；还公开了一种口服快速崩解片剂，其包括所述崩解颗粒组合物、活性物质和崩解剂。该崩解片具有良好的质地和口感、适当的硬度和良好的崩解性能，并能在潮湿条件下保持足够的硬度。
• USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE
  申请人：Japan Tobacco Inc.

  公开号：EP3685831A1

  公开（公告）日：2020-07-29

  The present invention relates to an agent for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases. According to the present invention, an agent containing ferric citrate as an active ingredient for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases can be provided.

  本发明涉及一种用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者缺铁性贫血的制剂。根据本发明，可以提供一种含有柠檬酸铁作为活性成分的制剂，用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者的缺铁性贫血。
• [EN] PLACENTAL CHONDROITIN SULPHATE A IMMUNOGENIC COMPOSITION AND APPLICATION<br/>[FR] COMPOSITION IMMUNOGÈNE CONTENANT DU SULFATE DE CHONDROÏTINE PLACENTAIRE A ET APPLICATION<br/>[ZH] 一种胎盘样硫酸软骨素A免疫组合物及应用
  申请人：SHENZHEN INST OF ADV TECH CAS

  公开号：WO2019075893A1

  公开（公告）日：2019-04-25

  本发明提供了包含胎盘样硫酸软骨素A的避孕用免疫组合物，所述免疫组合物中还包含免疫增强剂。本发明还提供了所述免疫组合物在制备用于人类及非人类动物避孕药物或阻止胚胎附植于子宫内膜的药物或中止妊娠的药物或免疫制剂中的用途。
• EP1385381A2
  申请人：——

  公开号：EP1385381A2

  公开（公告）日：2004-02-04
• EP1385381A4
  申请人：——

  公开号：EP1385381A4

  公开（公告）日：2005-02-09